Last 5 years
2024
Together with the Patient’s Association ANTIAN, our group starts a new project to develop a gene therapy strategy for the ADSL Deficiency. The starting event is the conference: “La raresa té dret a l’esperança. Per una teràpia gènica” together with a microfunding campaing. January 25th. Centre Cultural Cambrils.
2023
We participate in a Round Table: “What are the latest technological trends, innovations and challenges in advanced therapies?“, in the Unconference 2023. CataloniaBio & HealthTech. October 3rd.
We participate in the Genera Podcast to disseminate hottest topics in biomedicine to the general public. The episodes are available on the main podcast distribution platforms such as: Google Podcast, Apple Podcast, Podimo and Spotify, with free and open access to the public. Interview:”GENera | El presente de la medicina del futuro”. July 25th. Podcast
2022
The UPV has attended to the First TECNIO Congress celebrated at the Universitat de Girona. The aim of the conference was to identify the current challenges facing our knowledge transfer ecosystem. October 19th.
Members of the Catalan Parliament and the Spanish Congress of Deputies visited some of the TECNIO Association’s centres located (including ours -UPV-) on the Universitat Autònoma de Barcelona’s campus after having worked closely together on Catalonia’s new law on science. September 16th.
2021
Together with Patient’s Association “El Gen Rebelde”, we start a new project to develop a gene therapy strategy for GNB1 Encephalopathy at the Vall d’Hebron research Institute (VHIR). The starting event is a microfunding campaing. February 1st.
2020
Together with Patient’s Association “La Lucha de Abril”, we start a new project to develop a gene therapy strategy for Spastic Paraplegia 52 (SPG52) at the Universitat Autònoma de Barcelona. The starting event is a microfunding campaing. May 18th.
Highlights. Previous Years
2019. March 15th
The UPV has obtained the TECNIO Quality Accreditation by ACCIO (Generalitat de Catalunya).
This acreditation certifies the high quality standards of services and procedures of the UPV. Currently there are only about 60 entities with this recognition.
2018. August 23th
We are proud to announce that the UPV has recently obtained the ISO9001:2015 certification. ISO International Standards ensure that products and services are safe, reliable and have good quality.
2018. October 4th.
Dr. Miguel Chillón has received the I Transference Award by the Consell Social UAB due to his long record on technology transfer and valorization. Video-1 / Video-2
2017. December 12th
Klogene Therapeutics, Inc. and Kogenix Therapeutics, Inc. today announced the merger of the two companies. The combined company, using the name Klogene (Boston, USA), is focused on Klotho, a naturally occurring human protein that has been shown to have potential therapeutic effects in neurodegenerative diseases.
2016. November 8th
Dr. Miguel Chillón gives the conference “El envejecimiento del cerebro y sus terapias” at the Centre de Cultura Contemporànea de Barcelona (CCCB)
2016. September 15th
Dra. Assumpció Bosch and Dr. Miguel Chillón have co-founded Kogenix Therapeutics (Boston, USA), a company’s gene therapy mainly focused on klotho gene therapy enabling medical industry to provide treatment for Alzheimer’s disease and gene related disease through this gene therapy.
